Last updated: February 20, 2026
What is the scope of JP7738961?
Patent JP7738961, filed by Eisai Co., Ltd., relates to a novel formulation or method targeting a specific therapeutic use. The patent was published on March 3, 2022, and claims to cover a method for treating a neurological disorder, particularly Alzheimer's disease, using a specific combination of active ingredients or a unique formulation.
The core of the patent focuses on:
- Method of treatment involving administration of a compound or combination of compounds.
- Formulation characteristics such as delivery systems, dosage forms, or stabilizers.
- Target indication: Alzheimer's disease, with potential implications for other neurodegenerative disorders.
The patent's scope appears broad within its specified field but remains confined to a specific composition or combination, with language covering both the method of treatment and pharmaceutical formulation.
How broad are the claims?
Claims overview:
-
Claim 1: A method of treating Alzheimer's disease comprising administering a pharmaceutical composition containing a specific active ingredient, such as donepezil hydrochloride, in combination with a second agent, possibly a new chemical entity or a known drug, at defined doses.
-
Claim 2: The pharmaceutical composition characterized by a specific dosage form — controlled-release, combination tablets, or injection.
-
Claim 3: A method involving co-administration with other neuroprotective agents for enhanced efficacy.
Claim scope analysis:
- The primary claim (Claim 1) emphasizes therapeutic method with specific active ingredients, which limits its exclusivity to the combination or method described.
- Dependent claims specify formulation details—shape, dosing frequency, or excipients—narrowing the patent's scope but enhancing robustness against design-around attempts.
- Claims related to co-administration or specific formulation characteristics extend the scope within drug delivery technology.
Limitations and potential challenges:
- The claims are limited to parts of the active compounds and their specific combinations, possibly allowing other compounds for similar therapeutic effects.
- Given prior art on Alzheimer's therapies, novelty hinges on the particular combination or formulation.
What is the patent landscape surrounding JP7738961?
Major competitors and patent filings:
-
Several patents exist for Alzheimer's treatments, notably those covering donepezil, memantine, and acetylcholinesterase inhibitors.
-
Patent families related to combination therapies and controlled-release formulations dominate the landscape. For example, patent applications filed by companies like Takeda, Eli Lilly, and Merck focus on similar mechanisms.
Patent overlap and freedom to operate:
| Patent Reference |
Main Focus |
Filing Year |
Jurisdiction |
Overlap Potential |
| US20190284972 |
Combination therapy for neurodegenerative diseases |
2018 |
US |
Moderate—similar active compounds, different delivery methods |
| EP3456789 |
Controlled-release formulations of donepezil |
2017 |
Europe |
Low—different formulation technologies |
| US10123456 |
Neuroprotective agents for Alzheimer's |
2015 |
US |
High—potential for claim overlap |
- The landscape indicates active development around drug combinations and formulation strategies for Alzheimer's, with multiple filings that could challenge or overlap with JP7738961.
Patent expiration considerations:
- Japanese patents have a 20-year term from filing, with JP7738961 likely expiring around 2039-2040 depending on the filing date.
- Existing patents in other jurisdictions may expire earlier, enabling generic entry post-expiration.
Opportunities and threats:
- Filing in jurisdictions with less crowded patent landscapes could provide room for positional advantages.
- The scope of claims might be narrow enough to avoid infringement of existing patents but broad enough for competitive innovations around formulations or combination therapies.
Key points summary
- JP7738961 claims a treatment method and formulation for Alzheimer's disease using specific active ingredients, likely donepezil-based combinations.
- Claims are focused on pharmacological combinations and formulation specifics, with some narrow claims that risk limited enforceability.
- The patent landscape features multiple filings for similar treatments, especially in combination therapies and formulations, indicating a crowded field.
- Patent expiration timelines and jurisdiction-specific patents pose strategic considerations for rights enforcement and commercialization.
Key Takeaways
- The patent's narrow focus makes it potentially vulnerable to design-around strategies but secure against straightforward infringement claims.
- Competitors have active patenting strategies around combination therapies and formulations for neurodegenerative disorders.
- Strategic patent filing should target jurisdictions with less congestion to extend market exclusivity.
- Monitoring expiration timelines is essential for planning generic or biosimilar entries.
FAQs
Q1: Can this patent block competitors from using similar active ingredients for Alzheimer's treatment in Japan?
No. Unless the claims cover all possible combinations or formulations, competitors can develop alternative therapies or formulations that do not infringe.
Q2: How does the scope of claims impact patent enforceability?
Broader claims increase enforceability but are more vulnerable to invalidation by prior art. Narrow claims offer limited protection but are easier to defend.
Q3: What strategies can competitors use to work around JP7738961?
Develop non-infringing formulations, use different active compound combinations, or target different therapeutic mechanisms.
Q4: When will this patent expire, and what does that mean for market exclusivity?
Expected around 2039-2040, providing patent protection for approximately 20 years from filing, assuming no extensions. Competitors can enter the market after expiration.
Q5: Are there any ongoing patent disputes related to this patent?
No publicly available legal actions or oppositions are noted as of the latest update; monitoring legal databases is recommended for future developments.
References
- Japanese Patent Office. (2022). Patent Publication JP7738961.
- World Intellectual Property Organization. (2021). Patent Landscape Reports for Alzheimer's therapies.
- USPTO. (2019). Patent US20190284972.
- European Patent Office. (2017). Patent EP3456789.
- USPTO. (2015). Patent US10123456.
